ClinicalTrials.Veeva

Menu

Evaluation of the Potential Effects of LRP5 and Tph1 in the Pathogenesis of Periodontal Disease Individuals With Stage III Grade B Periodontitis

A

Ankara University

Status

Completed

Conditions

Periodontitis Stage III
Periodontitis (Stage 3)
Periodontal Disease

Study type

Observational

Funder types

Other

Identifiers

NCT06933797
36290600/03/2024
1919B012319473 (Other Grant/Funding Number)

Details and patient eligibility

About

Objectives: The aim of this study was to determine the changes in LRP5 and TPH1 levels in serum and saliva samples due to periodontal inflammation and to evaluate the relationship between these values and clinical periodontal parameters.

Methods: Saliva and serum samples were collected from 20 systemically healthy patients with Stage III periodontitis and 20 periodontally healthy control individuals. Salivary and serum LRP5 and TPH1 levels were analyzed using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters, including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL), were recorded.

Enrollment

40 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • >18 years old,
  • At least 16 permanent teeth except 3rd molars,
  • Individuals who do not use orthodontic appliances,
  • Individuals who are not pregnant or lactating,
  • Individuals without any systemic disease that may affect periodontal health,
  • Systemically healthy individuals,
  • Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
  • Individuals who have not received periodontal treatment in the last 1 year

Exclusion criteria

  • Pregnant/lactating individuals,
  • Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
  • Individuals who have undergone periodontal treatment in the last 1 year,
  • Individuals with psychiatric illness,
  • Individuals with any oral infection,
  • Individuals with <16 teeth, excluding molars,
  • Individuals with alcohol dependence,
  • Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
  • Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)

Trial design

40 participants in 2 patient groups

Stage III periodontitis
Description:
Individuals exhibiting pocket depths of \>3 mm in at least two non-adjacent teeth, radiographic evidence of alveolar bone loss extending to the middle or apical third of the root, and tooth loss of ≤4 due to periodontitis were classified as having Stage III periodontitis. The additional criterion for Grade B classification was defined as a % bone loss/age ratio of 0.25-1.
Periodontally healthy
Description:
Individuals with no signs of alveolar bone loss and an overall oral bleeding score \<10% were categorized as periodontally healthy.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems